Stoke Therapeutics Inc (STOK)

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire

Business Wire

Investors in Stoke Therapeutics (NASDAQ:STOK) have unfortunately lost 64% over the last three years - Yahoo Movies Canada

Yahoo Movies Canada

Taking the lead: Stoke Therapeutics Inc (STOK) – Sete News - SETE News

SETE News

Stoke Therapeutics (STOK) Price Target Decreased by 13.91% to 22.44 - MSN

MSN

Selling Buzz: Stoke Therapeutics Inc [STOK] CHIEF MEDICAL OFFICER Ticho Barry sells 10000 shares of the ... - Knox Daily

Knox Daily

When the Price of (STOK) Talks, People Listen - Stock Traders Daily

Stock Traders Daily

Stoke Therapeutics (NASDAQ:STOK) Trading Up 6.4% - MarketBeat

MarketBeat

STOK overperforms with a 10.82 increase in share price – US Post News - US Post News

US Post News

Stoke Therapeutics Inc (STOK) Becoming More Attractive for Investors – Knox Daily - Knox Daily

Knox Daily

Los Angeles Capital Management LLC Grows Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Defense World

Stoke Therapeutics (NASDAQ:STOK) Shares Down 6.4% - Defense World

Defense World

Stoke Therapeutics, Inc. (NASDAQ:STOK) Sees Significant Growth in Short Interest - MarketBeat

MarketBeat

Stoke Therapeutics, Inc. (NASDAQ:STOK) Forecasted to Post FY2024 Earnings of ($2.51) Per Share - Defense World

Defense World

Stoke Therapeutics (NASDAQ:STOK) Trading Down 6.4% - MarketBeat

MarketBeat

Stoke Therapeutics, Inc. Expected to Post FY2024 Earnings of ($2.51) Per Share (NASDAQ:STOK) - MarketBeat

MarketBeat

Research Analysts Issue Forecasts for Stoke Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:STOK) - Defense World

Defense World

Stoke Therapeutics (NASDAQ:STOK) Trading Down 6.4% - MarketBeat

MarketBeat

Stoke Therapeutics, Inc. (NASDAQ:STOK) Expected to Post FY2028 Earnings of $0.17 Per Share - MarketBeat

MarketBeat

Stoke Therapeutics Inc [STOK] Records 200-Day SMA of $6.19 – Knox Daily - Knox Daily

Knox Daily

Q2 2024 EPS Estimates for Stoke Therapeutics, Inc. (NASDAQ:STOK) Lowered by Wedbush - Defense World

Defense World

Stoke Therapeutics (NASDAQ:STOK) Given “Buy” Rating at HC Wainwright - Defense World

Defense World

Stoke Therapeutics (NASDAQ:STOK) Price Target Lowered to $20.00 at Canaccord Genuity Group - Defense World

Defense World

Stoke Therapeutics (NASDAQ:STOK) Rating Reiterated by Needham & Company LLC - Defense World

Defense World

The growth track for Stoke Therapeutics Inc (STOK) has changed recently – Sete News - SETE News

SETE News

Canaccord Genuity Group Trims Stoke Therapeutics (NASDAQ:STOK) Target Price to $20.00 - MarketBeat

MarketBeat

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates - citybiz

citybiz

Analyst Expectations For Stoke Therapeutics's Future

Benzinga

Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

Yahoo Finance

Stoke Therapeutics : Corporate Presentation - May 2024 - Marketscreener.com

Marketscreener.com

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates - Business Wire

Business Wire

Stoke Therapeutics (NASDAQ:STOK) Receives Buy Rating from Needham & Company LLC - MarketBeat

MarketBeat

Stoke therapeutics CMO sells $113,653 in stock By Investing.com - Investing.com

Investing.com

Stoke therapeutics CMO sells $113,653 in stock By Investing.com - Investing.com

Investing.com

It makes sense and dollars to buy Stoke Therapeutics Inc (STOK) stock – Sete News - SETE News

SETE News

Stoke Therapeutics Inc [STOK] Investment Appeal on the Rise – Knox Daily - Knox Daily

Knox Daily

Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline

Zacks Investment Research

Investor's Toolkit: Key Ratios for Assessing Stoke Therapeutics Inc (STOK)'s Performance – DWinneX - The Dwinnex

The Dwinnex

Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer - citybiz

citybiz

Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer - Business Wire

Business Wire

Stoke Therapeutics Chief Financial Officer Stephen Tulipano Resigns - MarketWatch

MarketWatch

Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline

Zacks Investment Research

Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline - Yahoo Finance

Yahoo Finance

Skorpios Trust sells $41.76 million of Stoke Therapeutics stock - Investing.com Canada

Investing.com Canada

Stoke Therapeutics, Inc. (NASDAQ:STOK) Major Shareholder Sells $41,760,000.00 in Stock - MarketBeat

MarketBeat

Dravet Syndrome Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes ... - openPR

openPR

Stoke Therapeutics' $125 Million Upsized Common Stock Offering – Global Legal Chronicle - Global Legal Chronicle

Global Legal Chronicle

Assessing Stoke Therapeutics: Insights From 6 Financial Analysts

Benzinga

Stoke Therapeutics Stock: Dravet Data Sends Shares Soaring One For Watchlist (NASDAQ:STOK) - Seeking Alpha

Seeking Alpha

Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist

Seeking Alpha

Stoke Therapeutics Launches Public Offering for Clinical Development - TipRanks.com - TipRanks

TipRanks